ENSC

Company Overview — What Does Ensysce Biosciences, Inc. Do?

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California. Ensysce Biosciences, Inc. (ENSC) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO D. Lynn Kirkpatrick, PhD and employs approximately 10 people. With a market capitalization of $2M, ENSC is one of the notable companies in the Healthcare sector.

Ensysce Biosciences, Inc. (ENSC) Stock Rating — Avoid (April 2026)

As of April 2026, Ensysce Biosciences, Inc. receives a Avoid rating with a composite score of 15.4/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.ENSC ranks #4,381 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Ensysce Biosciences, Inc. ranks #815 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

ENSC Stock Price and 52-Week Range

Ensysce Biosciences, Inc. (ENSC) currently trades at $0.47. The stock lost $0.01 (2.8%) in the most recent trading session. The 52-week high for ENSC is $4.85, which means the stock is currently trading -90.3% from its annual peak. The 52-week low is $0.31, putting the stock 49.6% above its annual trough. Recent trading volume was 183K shares, suggesting relatively thin trading activity.

Is ENSC Overvalued or Undervalued? — Valuation Analysis

Ensysce Biosciences, Inc. (ENSC) carries a value factor score of 7/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 1.85x, versus the sector average of 2.75x. The price-to-sales ratio is 1.02x, compared to 1.66x for the average Healthcare stock.

At current multiples, Ensysce Biosciences, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Ensysce Biosciences, Inc. Profitability — ROE, Margins, and Quality Score

Ensysce Biosciences, Inc. (ENSC) earns a quality factor score of 12/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -233.9%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -90.5% versus the sector average of -33.1%.

The operating margin is -296.3% (sector: -66.1%). Net profit margin stands at -294.8%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 171.2% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

ENSC Debt, Balance Sheet, and Financial Health

Ensysce Biosciences, Inc. has a debt-to-equity ratio of 158.0%, compared to the Healthcare sector average of 32.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 1.59x, suggesting adequate working capital coverage. Total debt on the balance sheet is $463,458. Cash and equivalents stand at $2M.

ENSC has a beta of 1.34, meaning it is more volatile than the broader market — a $10,000 investment in ENSC would be expected to move 34.3% more than the S&P 500 on any given day. The stability factor score for Ensysce Biosciences, Inc. is 14/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Ensysce Biosciences, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Ensysce Biosciences, Inc. reported revenue of $5M and earnings per share (EPS) of $-3.98. Net income for the quarter was $-7M. Gross margin was 0.0%. Operating income came in at $-5M.

In FY 2025, Ensysce Biosciences, Inc. reported revenue of $5M and earnings per share (EPS) of $-3.98. Net income for the quarter was $-10M. Revenue grew -2.8% year-over-year compared to FY 2024. Operating income came in at $-10M.

In Q3 2025, Ensysce Biosciences, Inc. reported revenue of $493,104 and earnings per share (EPS) of $-1.29. Net income for the quarter was $-4M. Revenue grew -85.6% year-over-year compared to Q3 2024. Operating income came in at $-4M.

In Q2 2025, Ensysce Biosciences, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.79. Net income for the quarter was $-2M. Operating income came in at $0.

Over the past 8 quarters, Ensysce Biosciences, Inc. has demonstrated a growth trajectory, with revenue expanding from $181,797 to $5M. Investors analyzing ENSC stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

ENSC Dividend Yield and Income Analysis

Ensysce Biosciences, Inc. (ENSC) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

ENSC Momentum and Technical Analysis Profile

Ensysce Biosciences, Inc. (ENSC) has a momentum factor score of 9/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 21/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 51/100 reflects moderate short selling activity.

ENSC vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Ensysce Biosciences, Inc. (ENSC) ranks #815 out of 838 stocks based on the Blank Capital composite score. This places ENSC in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing ENSC against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full ENSC vs S&P 500 (SPY) comparison to assess how Ensysce Biosciences, Inc. stacks up against the broader market across all factor dimensions.

ENSC Next Earnings Date

No upcoming earnings date has been announced for Ensysce Biosciences, Inc. (ENSC) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy ENSC? — Investment Thesis Summary

The quantitative profile for Ensysce Biosciences, Inc. suggests caution. The quality score of 12/100 flags below-average profitability. The value score of 7/100 indicates premium valuation. Momentum is weak at 9/100, a headwind for near-term performance. High volatility (stability score 14/100) increases portfolio risk.

In summary, Ensysce Biosciences, Inc. (ENSC) earns a Avoid rating with a composite score of 15.4/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on ENSC stock.

Related Resources for ENSC Investors

Explore more research and tools: ENSC vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare ENSC head-to-head with peers: ENSC vs AZN, ENSC vs SLGL, ENSC vs VMD.